There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report), Omeros (OMER – Research Report) and Urogen Pharma (URGN – Research Report) with bullish sentiments.
Oric Pharmaceuticals (ORIC)
In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals, with a price target of $17.00. The company’s shares closed last Monday at $10.75.
According to TipRanks.com, Biegler is a 1-star analyst with an average return of
Currently, the analyst consensus on Oric Pharmaceuticals is a Strong Buy with an average price target of $20.20, implying an 82.8% upside from current levels. In a report issued on March 26, J.P. Morgan also maintained a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Omeros (OMER)
In a report released today, Stephen Brozak from WBB Securities reiterated a Buy rating on Omeros, with a price target of $43.00. The company’s shares closed last Monday at $3.42.
Brozak has an average return of
According to TipRanks.com, Brozak is ranked #4929 out of 8796 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Omeros with a $43.00 average price target.
Urogen Pharma (URGN)
Oppenheimer analyst Leland Gershell maintained a Buy rating on Urogen Pharma today and set a price target of $34.00. The company’s shares closed last Monday at $13.21.
According to TipRanks.com, Gershell is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Urogen Pharma with a $35.33 average price target, implying a 159.0% upside from current levels. In a report issued on April 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $54.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ORIC:
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
- Oric Pharmaceuticals price target lowered to $18 from $19 at JPMorgan
- Oric Pharmaceuticals price target raised to $21 from $15 at H.C. Wainwright